MemoHoney Official Website › Articles › Evidence
EvidenceFractional Anisotropy: What The Brain Scan Trial Actually Measured
One imaging trial sits behind the protection claim on this kind of label, and it measured fractional anisotropy rather than memory.
Fractional anisotropy is a diffusion imaging score describing how directionally constrained water movement is in tissue. It is a structural measure, it is a long way upstream of remembering anything, and it is worth understanding before the trial is quoted.
The trial everybody reaches for
There is exactly one brain-imaging trial in the file behind this ingredient list, and because there is only one, it gets cited a great deal. It deserves to be read rather than quoted, because what it measured is not what a casual summary of it implies.
The paper gave beta-alanine, 2.4 g a day, to men and women aged 60 to 80 and reported improved fractional anisotropy scores in the hippocampus and the amygdala. Every word of that sentence is accurate. The question worth asking is what a fractional anisotropy score actually is.
Nothing below is medical advice, and MemoHoney is a supplement, not a treatment. A memory change that other people have noticed, or one that has grown steadily worse month on month, deserves an assessment rather than a purchase. MedlinePlus sets out what is worth reporting and to whom.
What fractional anisotropy measures
Water molecules in tissue move about randomly. In an open space they move equally in every direction, which is called isotropic diffusion. Inside a bundle of nerve fibres they cannot: the fibre walls and the fatty sheath around them constrain movement so that water travels much more freely along the bundle than across it.
Diffusion imaging measures that asymmetry, and fractional anisotropy is the number that expresses it, running from 0 for completely unconstrained movement to 1 for movement confined to a single axis. Higher scores are usually interpreted as more organised or better-preserved white matter.
That interpretation is standard, useful, and much softer than it sounds. Fractional anisotropy responds to several things at once, and telling them apart from the number alone is not possible.
- The density of fibres in the region being measured.
- The condition of the fatty myelin sheath around them.
- How parallel the fibres are to one another within a voxel.
- How much free fluid is in the tissue on the day of the scan.
- The scanner, the sequence and the analysis pipeline used.
The distance from a scan to a memory
A structural imaging measure is a long way upstream of an everyday outcome, and the chain between them has several unverified links.
A higher fractional anisotropy score in the hippocampus suggests better-organised white matter in a region involved in forming memories. It does not establish that the region works better, that the person remembers more, or that anybody around them would notice a difference. Those are three separate claims and the trial tested none of them.
| What was measured | What it supports | What it does not |
|---|---|---|
| Fractional anisotropy in the hippocampus | A structural change in a memory-related region | That memory improved |
| Fractional anisotropy in the amygdala | A structural change in an emotion-related region | That mood or anxiety changed |
| 2.4 g a day of beta-alanine | That this amount is enough to produce the change | That a smaller unprinted amount would |
| Adults aged 60 to 80 | That the population is the right one | That a younger buyer would respond the same way |
Four rows, four honest limits. None of them makes the trial a bad trial.
The carnosine trial that gets cited alongside it
A second study appears whenever this one does, and it is a different compound. The NEAT trial gave carnosine itself — 2 g a day for up to twelve weeks — and reported cognitive improvement in its younger participants.
Two things about that are worth holding. Carnosine is what beta-alanine is taken to raise, so the two are related but not interchangeable: swallowing carnosine and swallowing its precursor are different interventions with different pharmacokinetics. And the benefit in that trial was confined to the younger half of the sample, which is an awkward result to cite on a product aimed at older buyers.
Citing the pair together as though they were one body of evidence for one compound in one population is the most common mistake made with this literature.
Read the MemoHoney label while this is in front of you
Six named ingredients, the amount each published trial used printed beside them, and 60 days from the date of purchase to decide.
Two bottles $158 · six bottles $294 · 60-day money-back guarantee
Order MemoHoney From This CounterLot MEM-26/ME-8302 · one a morning, 30 to a bottle · ships from the United States
Where the rest of the beta-alanine evidence lives
It is large, it is decent quality, and it is about exercise. A systematic review and meta-analysis pooled the exercise-capacity trials and produced an effect size of 0.18 at 3.2 to 6.4 g a day. That is small but real, and it is the strongest thing anybody can say about this ingredient.
On safety the file is reassuring and specific. A systematic risk assessment found paraesthesia — the tingling — to be the only consistent adverse effect up to 6.4 g a day and identified nothing else, and an evidence review written for military use reached the same conclusion.
So the position is: well tolerated, useful for exercise capacity at gram scale, and supported for cognition by a single imaging trial at 2.4 g a day.
Why none of this can be applied to the capsule
Every figure in this article is an amount, and the artwork supplied with this product prints none. The imaging trial used 2.4 g a day of beta-alanine alone. A capsule of this size holds a few hundred milligrams of powder in total, shared between six ingredients.
That arithmetic is set out properly on the dosage analysis rather than argued again here. What belongs on this page is the narrower point: even if the amount were printed and even if it matched, the trial it would match measured a scan in eighty people, once.
- One trial is one trial, however good.
- A structural imaging measure is not a cognitive outcome.
- A precursor is not the compound it raises.
- A published amount is the minimum a reader needs before any of this becomes relevant to a bottle.
Why there is only one imaging trial
Because they are expensive and slow. A diffusion imaging study needs scanner time at both ends, a trained analysis team and participants willing to lie still twice, months apart. A performance trial needs a gym, a stopwatch and an afternoon.
That economics explains the entire shape of this evidence base. The cheap question gets asked a hundred times and the expensive one gets asked once, and the single expensive answer then has to carry the weight of a whole marketing category. It is not a reason to distrust the trial. It is a reason to stop treating one result as settled.
It is also why the honest response to a single imaging study is a second one rather than a label claim. Replication is how a finding becomes a fact, and nothing in this file has been replicated.
The words a label reaches for instead
The seller's own account of this ingredient describes it as raising carnosine and shielding neurons from age-related wear, and calls the result a shield that preserves brain cells from deterioration.
Set that beside what the trial measured — a diffusion score in two regions, in eighty people, once — and the distance is the point of this article. Shield is a strong word doing the work of a weak result, and it is the kind of sentence a structure and function claim is allowed to make precisely because it is vague enough not to be testable.
| The claim | What it would take to support it |
|---|---|
| Protects neurons from oxidative stress | A measure of oxidative damage, before and after, against placebo |
| Preserves brain cells from deterioration | Years of follow-up and a measure of cell loss |
| Improves mental clarity | A validated cognitive battery, against placebo, in the right population |
None of the three has been measured for this compound in this population. The benefits page reads all five of the seller's statements the same way.
How to read the next imaging claim you meet
- Find the outcome measure and look it up. Fractional anisotropy, cortical thickness and regional volume are all structural, and none is a test score.
- Check the sample size and whether the effect held across the whole group or only part of it.
- Check whether the compound in the trial is the compound in the bottle.
- Check the amount, then check whether the format can hold it.
- Ask whether anybody has repeated it. One positive imaging study is a reason for a second study, not for a claim on a label.
That 2.4 g a day of beta-alanine, taken by adults aged 60 to 80, was associated with a structural imaging change in two brain regions. That is a real finding and a modest one, and it is the entire cognitive evidence base for this ingredient.
- Ostfeld I, Zamir A, Ben-Zeev T, et al: “β-Alanine supplementation improves fractional anisotropy scores in the hippocampus and amygdala in 60-80-year-old men and women” · Exp Gerontol, 2024 · 194:112513 · PMID 38971131.
- O'Toole TE, Amraotkar AR, Gao H, et al: “Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial” · Neurotherapeutics, 2025 · 22(2):e00541 · PMID 39919936.
- Saunders B, Elliott-Sale K, Artioli GG, et al: “β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis” · Br J Sports Med, 2017 · 51(8):658-669 · PMID 27797728.
- Dolan E, Swinton PA, Painelli VS, et al: “A Systematic Risk Assessment and Meta-Analysis on the Use of Oral β-Alanine Supplementation” · Adv Nutr, 2019 · 10(3):452-463 · PMID 30980076.
- Ko R, Low Dog T, Gorecki DK, et al: “Evidence-based evaluation of potential benefits and safety of beta-alanine supplementation for military personnel” · Nutr Rev, 2014 · 72(3):217-25 · PMID 24697258.
- Memory, from MedlinePlus, US National Library of Medicine (medlineplus.gov).
- Using Dietary Supplements Wisely, from National Center for Complementary and Integrative Health, National Institutes of Health (nccih.nih.gov).
